Business
Enrolment for AxisBiotix-PsT study commences
Enrolment for AxisBiotix-PsT study commences.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4707L\n SkinBioTherapeutics PLC\n 13 January 2021\n \n \n \n \n 13 January 2021\n \n \n SkinBioTherapeutics plc\n \n \n \n \n \n (\"SkinBioTherapeutics\" or \"the Company\")\n \n \n \n Enrolment for \n \n \n AxisBiotix-Ps™ food supplement consumer study commences \n \n \n \n \n \n \n · \n Enrolment commenced for the AxisBiotix-Ps™ food supplement consumer study\n \n · \n Targeting 200+ applicants, study will be monitored through a smart phone application \n \n \n · \n Study due to commence in February 2021\n \n \n \n \n \n SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that \n AxisBiotix Limited, a wholly owned subsidiary of the Company, has commenced enrolment for its food supplement\n consumer study.\n \n \n \n \n \n \n AxisBiotix-Ps\n \n ™\n \n food supplement consumer study\n \n \n \n \n \n \n Further to research exploring the relationship between the gut and the skin and the scientific evidence pointing to a link between gut dysfunction, stress-induced alterations to the gut microbiome and skin inflammation, the Company has been working with Winclove Probiotics B.V. (\"Winclove\") for the development of a blend of bacterial strains as a food supplement. \n \n \n \n \n \n A proprietary blend of bacterial strains has been specifically designed to balance the gut microbiome to address the over production of new skin cells often seen in aggressive skin conditions such as psoriasis. Psoriasis is a debilitating skin condition caused by a malfunction of the immune system whereby raised 'plaques' form on the skin, which can be flaky, scaly and itchy. There is currently no cure for psoriasis; therapies tend to be steroid-based, which cannot be used long term and have side effects. The condition is common, with approximately 2% of the global population believed to suffer from psoriasis.\n \n \n \n \n \n With Winclove having completed formulation and manufacture of the supplement, and unable to initiate its clinic based human study due to the Covid-19 restrictions, the Company has established a protocol for a 'self-managed' food supplement study. \n \n \n \n \n \n The study, which will accept approximately 200 applicants, is now open for enrolment through the website \n \n www.axisbiotix.com\n \n . The particip...